# A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

> **NCT03383458** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 545 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03383458
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-18
- **Primary completion:** 2026-02-27
- **Final completion:** 2031-02-27
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383458, "A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03383458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*